, Volume 25, Issue 2, pp 112–116 | Cite as

Multifocal osteoarthritis due toCandida albicans in a neonate: Serum level monitoring of liposomal amphotericin B and literature review

  • J. Evdoridou
  • G. Kremenopoulos
  • E. Roilides
  • E. Bibashi
Brief Report


A 32-week neonate weighing 2,300 g at birth with fungemia due toCandida albicans subsequently developed multifocal osteoarthritis of the lower extremities due to the same organism during therapy with amphotericin B (0.5 mg/kg/day) and flucytosine (100 mg/kg/day) to which the isolates were susceptible. Liposomal amphotericin B (3.5 mg/kg/day) was substituted for conventional amphotericin B and complete clinical and radiologic recovery as well as sterilization of affected joints were achieved with a 38-day-course (144.5 mg/kg total). Adequate drug concentrations in serum and synovial fluid were attained with liposomal amphotericin B. Nine neonates (≤28 days of age) with bone and/or joint infections due toCandida spp. had previously been reported in the English-language literature. To our knowledge, the present case is the first reported cure with liposomal amphotericin B. Previous cases are reviewed and the potential role of liposomal amphotericin B in this serious neonatal infection is discussed.


Osteoarthritis Drug Concentration Lower Extremity Amphotericin Synovial Fluid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Feigin, R. D., Adcock, L. M., Edwards, M. S. Fungal and protozoal infections. In:Fanaroff, A. A., Martin, R. J. (eds.): Neonatal-perinatal medicine — diseases of the fetus and infant. Mosby-Year Book Inc, St Louis 1992, pp. 683–690.Google Scholar
  2. 2.
    Anderson, D. C., Pickering, L. K., Feigin, R. D. Leukocyte function in normal and infected neonates. J. Pediatr. 85 (1974) 420–425.PubMedGoogle Scholar
  3. 3.
    Shigeoka, A. O., Charette, R. P., Wyman, M. L., Hill, H. R. Defective oxidative metabolic responses of neutrophils from stressed neonates. J. Pediatr. 98 (1981) 392–398.PubMedGoogle Scholar
  4. 4.
    Cairo, M. S. Neonatal neutrophil host defense. Prospects for immunologic enhancement during neonatal sepsis. Am. J. Dis. Child 143 (1989) 40–46.PubMedGoogle Scholar
  5. 5.
    Faix, R. G. Invasive neonatal candidiasis: comparison ofalbicans andparapsilosis infection. Pediatr. Infect. Dis. J. 11 (1992) 88–93.PubMedGoogle Scholar
  6. 6.
    Butler, K. M., Baker, C. J. Candida: an increasingly important pathogen in the nursery. Pediatr. Clin. North Am. 35 (1988) 543–563.PubMedGoogle Scholar
  7. 7.
    Wong, M., Isaacs, D., Howman-Gils, R., Uren, R. Clinical and diagnostic features of osteomyelitis occurring in the first 3 months of life. Pediatr. Infect. Dis. J. 14 (1995) 1047–1053.PubMedGoogle Scholar
  8. 8.
    Svirsky-Fein, S., Langer, L., Milbauer, B., Khermosh, O., Rubinstein, E. Neonatal osteomyelitis caused byCandida tropicalis. Report of two cases and review of the literature. J. Bone Joint Surg. 61 (1979) 455–459.PubMedGoogle Scholar
  9. 9.
    Oleinik, E. M., Della-Latta, P., Rinaldi, M. G., Seiman, L. Candida lusitaniae osteomyelitis in a premature infant. Am. J. Perinatol. 10 (1993) 313–315.PubMedGoogle Scholar
  10. 10.
    Ward, R. M., Sattler, F. R., Dalton, A. S. Assessment of antifungal therapy in an 800-gram infant with candidal arthritis and osteomyelitis. Pediatrics 72 (1983) 234–238.PubMedGoogle Scholar
  11. 11.
    Gathe, J. C., Harris, R. L., Garland, B., Bradshaw, M. W., Williams, T. W. Candida osteomyelitis. Report of five cases and review of the literature. Am. J. Med. 82 (1987) 927–937.CrossRefPubMedGoogle Scholar
  12. 12.
    National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts; proposed standard. NCCLS document M27-P (ISBN 1-56238-186-5). NCCLS, Villanova, PA 1992.Google Scholar
  13. 13.
    Pruitt, A. W., Achord, J. L., Fales, F. W., Patterson, J. H. Glucosegalactose malabsorption complicated by monilial arthritis. Pediatrics 43 (1969) 106–110.PubMedGoogle Scholar
  14. 14.
    Adler, S., Randall, J., Plotkin, S. A. Candidal osteomyelitis and arthritis in a neonate. Am. J. Dis. Child 123 (1972) 595–596.PubMedGoogle Scholar
  15. 15.
    Freeman, J. B., Wienke, J. W., Soper, R. T. Candida osteomyelitis associated with intravenous alimentation. J. Pediatr. Surg. 9 (1974) 783–784.CrossRefPubMedGoogle Scholar
  16. 16.
    Pittard, W. B., Thullen, J. D., Fanaroff, A. A. Neonatal septic arthritis. J. Pediatr. 88 (1976) 621–624.PubMedGoogle Scholar
  17. 17.
    Omene, J. A., Odita, J. C., Okolo, A. A. Neonatal osteomyelitis in Nigerian infants. Pediatr. Radiol. 14 (1984) 318–322.CrossRefPubMedGoogle Scholar
  18. 18.
    Pope, T. L. PediatricCandida albicans arthritis: case report of hip involvement with a review of the literature. Prog. Pediatr. Surg. 15 (1982) 271–283.PubMedGoogle Scholar
  19. 19.
    Beck-Sague, C. M., Jarvis, W. R., the National Nosocomial Infections Surveillance System Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990. J. Infect. Dis. 167 (1993) 1247–1251.PubMedGoogle Scholar
  20. 20.
    Dan, M. Septic arthritis in young infants: clinical and microbiologic correlations and therapeutic implications. Rev. Infect. Dis. 6 (1984) 147–155.PubMedGoogle Scholar
  21. 21.
    Weese-Mayer, D. E., Wheeler Fondriest, D., Brouillette, R. T., Shulman, S. T. Risk factors associated with candidemia in the neonatal intensive care unit: a case-control study. Pediatr. Infect. Dis. J. 6 (1987) 190–196.PubMedGoogle Scholar
  22. 22.
    Van den Anker, J. N., van Popele, N. M. L., Sauer, P. J. J. Antifungal agents in neonatal systemic candidiasis. Antimicrob. Agents Chemother. 39 (1995) 1391–1397.PubMedGoogle Scholar
  23. 23.
    Farrell, J. B., Person, D. A., Lidsky, M. D., Hopfer, R. L., Musher, D. M. Candida tropicalis arthritis-assessment of amphotericin B therapy. J. Rheumatol. 5 (1978) 267–271.PubMedGoogle Scholar
  24. 24.
    Weisse, M. E., Person, D. A., Berkenbaugh, J. T. Treatment ofCandida arthritis with flucytosine and amphotericin B. J. Perinatol. 13 (1993) 402–404.PubMedGoogle Scholar
  25. 25.
    Lopez-Berestein, G., Bodey, G. P., Fainstein, V., Keating, M., Frankel, L., Zeluff, B., Gentry, L., Mehta, K. Treatment of systemic fungal infections with liposomal amphotericin B. Arch. Intern. Med. 149 (1989) 2533–2536.CrossRefPubMedGoogle Scholar
  26. 26.
    Vincent, M., Webster, M. H., Pether, J. V. S. Liposomal amphotericin B. Lancet 339 (1992) 374–375.CrossRefGoogle Scholar
  27. 27.
    Lackner, H., Schiwinger, W., Urban, C., Muller, W., Ritschl, E., Reiterer, F., Kuttnig-Haim, M., Urlesberger, B., Hauer, C. Liposomal amphotericin-B (AmBisome) for treatment of disseminated fungal infections in two infants of very low birth weight. Pediatrics 89 (1992) 1259–1261.PubMedGoogle Scholar
  28. 28.
    daSilva, L. P., Amaral, J. M. V., Ferreira, N. C. Which is the most appropriate dosage of liposomal amphotericin B (AmBisome) for the treatment of fungal infections in infants of very low birth weight? Pediatrics 91 (1993) 1217–1218.Google Scholar
  29. 29.
    Bennett, J. E. Antifungal agents. In:Mandell, G. L., Bennett, J. E., Dolin, R. (eds.): Principles and practice of infectious diseases. Churchill Livingstone, New York 1995, pp. 401–410.Google Scholar

Copyright information

© MMV Medizin Verlag GmbH München 1997

Authors and Affiliations

  • J. Evdoridou
    • 1
  • G. Kremenopoulos
    • 1
  • E. Roilides
    • 3
  • E. Bibashi
    • 2
  1. 1.Dept. of NeonatologyUniversity of Thessaloniki, Hippokration HospitalThessalonikiGreece
  2. 2.Dept. of MicrobiologyUniversity of Thessaloniki, Hippokration HospitalThessalonikiGreece
  3. 3.3rd Dept. of PediatricsUniversity of Thessaloniki, Hippokration HospitalThessalonikiGreece

Personalised recommendations